产品
编 号：F442004
分子式：C18H18N8O7S3
分子量：554.58
分子式：C18H18N8O7S3
分子量：554.58
产品类型
规格
价格
是否有货
100mg
询价
询价
结构图
CAS No: 73384-59-5
产品详情
生物活性：
Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis.
体内研究：
Ceftriaxone (200 mg/kg, 腹腔注射, 连续 6 周) 在 D-半乳糖 (DGL) 诱导的大鼠肝肾损伤模型中可改善功能指标，以及氧化应激和炎症参数。Ceftriaxone (200, 400 mg/kg, 腹腔注射) 对大鼠 Pentylenetetrazol (PTZ) 致惊厥及PTZ 相关氧化损伤具有保护作用。Ceftriaxone (100, 200 mg/kg, 腹腔注射) 在 Streptozocin (HY-13753) 诱导的糖尿病大鼠模型中通过激活 GLT-1 减少机械性异常性痛和痛觉过敏。Animal Model:DGL-induced rat model
Dosage:200 mg/kg
Administration:i.p.
Result:Reduced the BUN、Cr 、AST and ALT levels.Attenuated the MDA levels and enhanced GPx and CAT activities.Reduced the levels of IL-1β and TNF-α mRNA.
Animal Model:PTZ-induced rat model
Dosage:200, 400 mg/kg
Administration:i.p. 60 min before to PTZ (70 mg/kg)
Result:Both of the two ceftriaxone groups had lower spike percentages than the saline group.Significantly lower MDA levels and higher SOD activity in 200 and 400 mg/kg.
体外研究：
Ceftriaxone (100 μM, 24 h) 通过抑制 NF-κB /JNK/c-Jun 信号通路保护被 MPP+ 处理的星形细胞。Ceftriaxone (500 μM, 24-48 h) 通过抑制极光激酶 B (Aurora B) 有效抑制 A549、H520 和H1650 肺癌细胞的非锚定细胞生长。
Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis.
体内研究：
Ceftriaxone (200 mg/kg, 腹腔注射, 连续 6 周) 在 D-半乳糖 (DGL) 诱导的大鼠肝肾损伤模型中可改善功能指标，以及氧化应激和炎症参数。Ceftriaxone (200, 400 mg/kg, 腹腔注射) 对大鼠 Pentylenetetrazol (PTZ) 致惊厥及PTZ 相关氧化损伤具有保护作用。Ceftriaxone (100, 200 mg/kg, 腹腔注射) 在 Streptozocin (HY-13753) 诱导的糖尿病大鼠模型中通过激活 GLT-1 减少机械性异常性痛和痛觉过敏。Animal Model:DGL-induced rat model
Dosage:200 mg/kg
Administration:i.p.
Result:Reduced the BUN、Cr 、AST and ALT levels.Attenuated the MDA levels and enhanced GPx and CAT activities.Reduced the levels of IL-1β and TNF-α mRNA.
Animal Model:PTZ-induced rat model
Dosage:200, 400 mg/kg
Administration:i.p. 60 min before to PTZ (70 mg/kg)
Result:Both of the two ceftriaxone groups had lower spike percentages than the saline group.Significantly lower MDA levels and higher SOD activity in 200 and 400 mg/kg.
体外研究：
Ceftriaxone (100 μM, 24 h) 通过抑制 NF-κB /JNK/c-Jun 信号通路保护被 MPP+ 处理的星形细胞。Ceftriaxone (500 μM, 24-48 h) 通过抑制极光激酶 B (Aurora B) 有效抑制 A549、H520 和H1650 肺癌细胞的非锚定细胞生长。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备